When to believe a subgroup analysis: revisiting the 11 criteria.
作者信息
Farrokhyar Forough, Skorzewski Philip, Phillips Mark R, Garg Sunir J, Sarraf David, Thabane Lehana, Bhandari Mohit, Chaudhary Varun
机构信息
Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada.
Department of Surgery, McMaster University, Hamilton, ON, Canada.
出版信息
Eye (Lond). 2022 Nov;36(11):2075-2077. doi: 10.1038/s41433-022-01948-0. Epub 2022 Jan 31.
Abstract
摘要
相似文献
1
When to believe a subgroup analysis: revisiting the 11 criteria.何时相信亚组分析：重温11条标准
Eye (Lond). 2022 Nov;36(11):2075-2077. doi: 10.1038/s41433-022-01948-0. Epub 2022 Jan 31.
2
[A comparative study of how subjects' characteristics and nursing service quality influence on hospital revisiting intent between patients and nurses].一项关于患者与护士的特征及护理服务质量如何影响患者再次入院意愿的对比研究
Taehan Kanho Hakhoe Chi. 2005 Dec;35(7):1210-20. doi: 10.4040/jkan.2005.35.7.1210.
3
Choice of glucocorticoid in HELLP syndrome - dexamethasone versus betamethasone: revisiting the dilemma.HELLP综合征中糖皮质激素的选择——地塞米松与倍他米松：重新审视这一困境。
J Matern Fetal Neonatal Med. 2012 Dec;25(12):2597-600. doi: 10.3109/14767058.2012.712571. Epub 2012 Aug 24.
4
Revisiting Rosacea Criteria: Where Have We Been, Where Are We Going, and How Will We Get There?重新审视酒渣鼻的诊断标准：我们从哪里来，要到哪里去，以及如何到达那里？
Dermatol Clin. 2018 Apr;36(2):161-165. doi: 10.1016/j.det.2017.11.011. Epub 2017 Nov 29.
5
Solitary melanoma confined to the dermal and/or subcutaneous tissue: evidence for revisiting the staging classification.局限于真皮和/或皮下组织的孤立性黑色素瘤：重新审视分期分类的证据
Arch Dermatol. 2000 Nov;136(11):1397-9. doi: 10.1001/archderm.136.11.1397.
6
Debate: Subgroup analyses in clinical trials: fun to look at - but don't believe them!辩论：临床试验中的亚组分析：看着有趣——但别信它们！
Curr Control Trials Cardiovasc Med. 2000;1(1):25-27. doi: 10.1186/cvm-1-1-025.
7
Revisiting hospital readmissions.再谈医院再入院问题。
Hosp Pharm. 2013 Dec;48(11):970-1. doi: 10.1310/hpj4811-970.
8
Revisiting Criteria for Psychosis in Alzheimer's Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research.重新审视阿尔茨海默病及相关痴呆症中精神病的标准：迈向更好的表型分类和生物标志物研究
J Alzheimers Dis. 2020;73(3):1143-1156. doi: 10.3233/JAD-190828.
9
Issues related to subgroup analysis in clinical trials.临床试验中的亚组分析相关问题。
J Biopharm Stat. 2002 Aug;12(3):347-58. doi: 10.1081/bip-120014565.
10
Estimates of subgroup treatment effects in overall nonsignificant trials: To what extent should we believe in them?总体无显著意义试验中各亚组治疗效果的估计：我们应在多大程度上相信这些估计？
Pharm Stat. 2017 Jul;16(4):280-295. doi: 10.1002/pst.1810. Epub 2017 May 15.
引用本文的文献
1
Effect of age on the efficacy and safety of Panax notoginseng saponins in acute ischemic stroke: a prespecified secondary analysis of the PANDA study.年龄对三七总皂苷治疗急性缺血性卒中疗效和安全性的影响：PANDA研究的一项预先设定的二次分析
Chin Med. 2025 Apr 15;20(1):51. doi: 10.1186/s13020-025-01101-5.
2
Digital Cognitive Behavioral Therapy for Panic Disorder and Agoraphobia: A Meta-Analytic Review of Clinical Components to Maximize Efficacy.针对惊恐障碍和场所恐惧症的数字认知行为疗法：对临床组成部分的荟萃分析综述以实现疗效最大化
J Clin Med. 2025 Mar 6;14(5):1771. doi: 10.3390/jcm14051771.
3
The hazards of chasing subgroups in neutral stroke trials.中性卒中试验中追踪亚组的风险。
Neurol Res Pract. 2025 Mar 11;7(1):17. doi: 10.1186/s42466-025-00369-0.
4
The serum level of vitamin D and prevalence of vitamin D deficiency among children with asthma in Asia and Africa: a systematic review and meta-analysis.亚洲和非洲哮喘儿童的维生素D血清水平及维生素D缺乏症患病率：一项系统评价和荟萃分析。
Arch Public Health. 2024 Jul 5;82(1):103. doi: 10.1186/s13690-024-01321-5.
5
Comparison of the Working Alliance in Blended Cognitive Behavioral Therapy and Treatment as Usual for Depression in Europe: Secondary Data Analysis of the E-COMPARED Randomized Controlled Trial.比较混合认知行为疗法与欧洲常规治疗抑郁症的工作联盟：E-COMPARED 随机对照试验的二次数据分析。
J Med Internet Res. 2024 May 31;26:e47515. doi: 10.2196/47515.
6
Pulmonary artery pressure monitoring in chronic heart failure: effects across clinically relevant subgroups in the MONITOR-HF trial.慢性心力衰竭肺动脉压监测：MONITOR-HF 试验中临床相关亚组的影响。
Eur Heart J. 2024 Aug 21;45(32):2954-2964. doi: 10.1093/eurheartj/ehae323.
7
Estimate the burden of malnutrition among children with cerebral palsy in Sub-Saharan Africa: a systematic review with meta-analysis.估算撒哈拉以南非洲脑瘫儿童营养不良的负担：系统评价与荟萃分析。
Sci Rep. 2024 Mar 18;14(1):6494. doi: 10.1038/s41598-024-55730-1.
8
The credibility of subgroup analyses reported in stroke trials is low: A systematic review.亚组分析在卒中试验中的可信度较低：一项系统评价。
Int J Stroke. 2023 Dec;18(10):1161-1168. doi: 10.1177/17474930231168517. Epub 2023 May 2.
9
Association Between Visual Acuity and Fluid Compartments with Treat-and-Extend Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: An ARIES Post Hoc Analysis.新生血管性年龄相关性黄斑变性中视力与玻璃体腔注射阿柏西普治疗并延长给药方案的液体积聚之间的关联：一项ARIES事后分析
Ophthalmol Ther. 2022 Jun;11(3):1119-1130. doi: 10.1007/s40123-022-00491-1. Epub 2022 Mar 18.
本文引用的文献
1
Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.替普罗单抗治疗活动性甲状腺眼病患者：两项随机、双盲、安慰剂对照、多中心试验的汇总数据分析、亚组分析及停药后随访结果
Lancet Diabetes Endocrinol. 2021 Jun;9(6):360-372. doi: 10.1016/S2213-8587(21)00056-5. Epub 2021 Apr 15.
2
A systematic review of subgroup analyses in randomised clinical trials in cardiovascular disease.系统评价心血管疾病随机临床试验中的亚组分析。
Clin Trials. 2021 Jun;18(3):351-360. doi: 10.1177/1740774520984866. Epub 2021 Jan 21.
3
Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses.随机对照试验和荟萃分析中效应修饰分析可信度评估工具（ICEMAN）的开发。
CMAJ. 2020 Aug 10;192(32):E901-E906. doi: 10.1503/cmaj.200077.
4
Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.托珠单抗与硫唑嘌呤治疗高复发视神经脊髓炎谱系疾病的安全性和有效性（TANGO）：一项开放标签、多中心、随机、2 期临床试验。
Lancet Neurol. 2020 May;19(5):391-401. doi: 10.1016/S1474-4422(20)30070-3.
5
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results.雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性：两年结果。
Ophthalmology. 2020 Apr;127(4S):S135-S145. doi: 10.1016/j.ophtha.2020.01.029.
6
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients With Diabetic Macular Edema Involving the Center of the Macula and Good Visual Acuity: A Randomized Clinical Trial.阿柏西普与激光光凝及观察治疗对中心性浆液性脉络膜视网膜病变黄斑区累及及良好视力患者视力丧失影响的随机临床试验
JAMA. 2019 May 21;321(19):1880-1894. doi: 10.1001/jama.2019.5790.
7
Efficacy of Omega-3 Fatty Acid Supplementation for Treatment of Dry Eye Disease: A Meta-Analysis of Randomized Clinical Trials.补充ω-3脂肪酸治疗干眼症的疗效：一项随机临床试验的荟萃分析。
Cornea. 2019 May;38(5):565-573. doi: 10.1097/ICO.0000000000001884.
8
Subgroup analysis and interaction tests: why they are important and how to avoid common mistakes.亚组分析与交互作用检验：为何它们很重要以及如何避免常见错误。
J Bras Pneumol. 2017 May-Jun;43(3):162. doi: 10.1590/S1806-37562017000000170.
9
General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trials.晚期临床试验中探索性和确证性子组分析的一般指南。
J Biopharm Stat. 2016;26(1):71-98. doi: 10.1080/10543406.2015.1092033.
10
Credibility of claims of subgroup effects in randomised controlled trials: systematic review.随机对照试验中亚组效应的可信性声称：系统评价。
BMJ. 2012 Mar 15;344:e1553. doi: 10.1136/bmj.e1553.
Zotero 插件